Lanitop (Metildigoxin)

Metildigoxin, the active ingredient in Lanitop, is a cardiac glycoside presented as an oral tablet for oral use. It is used to treat heart failure and control ventricular response in atrial fibrillation in adult patients.

GNH USA supplies Lanitop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metildigoxin is employed in cardiovascular therapy to improve cardiac performance and rhythm control. - Heart failure: improves ventricular contractility and reduces symptoms of fluid overload. - Atrial fibrillation: helps control ventricular rate by slowing atrioventricular conduction. - Cardiac arrhythmias: stabilizes abnormal heart rhythms when other therapies are insufficient.

Metildigoxin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Blurred vision - Fatigue

Serious or Rare Side Effects: - Life‑threatening arrhythmias (e.g., ventricular tachycardia) - Severe bradycardia or heart block - Hyperkalemia - Allergic reactions such as skin rash or anaphylaxis

When prescribing Metildigoxin, clinicians should consider several safety precautions. - Renal impairment: monitor serum drug levels and renal function. - Electrolyte disturbances: avoid use in patients with hyperkalemia or hypomagnesemia. - Thyroid disease: use with caution in hyper‑ or hypothyroidism. - Elderly patients: start at lower doses due to increased sensitivity. - Concomitant medications: review all drugs for potential interactions. - Store at ambient temperature: keep in original container, protect from moisture and light.

Metildigoxin interacts with several medicines that can alter its concentration or cardiac effects.

Major Interactions (Avoid): - Potassium‑sparing diuretics: may precipitate hyperkalemia and toxicity. - Amiodarone: increases serum Metildigoxin levels, raising risk of toxicity. - Macrolide antibiotics (e.g., erythromycin): inhibit metabolism and elevate drug concentrations.

Moderate Interactions (Monitor Closely): - Beta‑blockers: additive negative chronotropic effect, may require dose adjustment. - ACE inhibitors: can enhance hypotensive response. - NSAIDs: may reduce renal clearance of Metildigoxin.